<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font22 { font-size : 22; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">(.) </span>
   <span class="font22">patients </span>
   <span class="font16">CNS </span>
   <span class="font15">ASCT </span>
   <span class="font15">lymphoma </span>
   <span class="font15">primary </span>
   <span class="font14">CI, </span>
   <span class="font14">PCNSL </span>
   <span class="font14">central </span>
   <span class="font14">nervous </span>
   <span class="font14">transplantation </span>
   <span class="font14">rate </span>
   <span class="font13">PFS </span>
   <span class="font13">autologous </span>
   <span class="font13">cell </span>
   <span class="font13">chemotherapy </span>
   <span class="font13">undergone </span>
   <span class="font13">conditioning </span>
   <span class="font12">stem </span>
   <span class="font12">-year </span>
   <span class="font12">TBC </span>
   <span class="font12">.-. </span>
   <span class="font12">reported </span>
   <span class="font12">study </span>
   <span class="font12">Oncol </span>
   <span class="font12">(.-.) </span>
   <span class="font12">HDC/ASCT </span>
   <span class="font12">Reference </span>
   <span class="font12">using </span>
   <span class="font12">{border-style </span>
   <span class="font12">data </span>
   <span class="font12">Clin </span>
   <span class="font12">px;} </span>
   <span class="font12">relapse </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">high-dose </span>
   <span class="font11">SCNSL </span>
   <span class="font11">survival </span>
   <span class="font11">cyclophosphamide </span>
   <span class="font11">involvement </span>
   <span class="font11">secondary </span>
   <span class="font11">disease </span>
   <span class="font11">including </span>
   <span class="font11">lymphoma: </span>
   <span class="font11">SCNSL/CNS </span>
   <span class="font11">busulfan, </span>
   <span class="font11">thiotepa, </span>
   <span class="font11">High-dose </span>
   <span class="font11">Patients </span>
   <span class="font11">Table </span>
   <span class="font11">WBRT </span>
   <span class="font11">consolidation </span>
   <span class="font11">median </span>
   <span class="font11">patients, </span>
   <span class="font11">respectively. </span>
   <span class="font11">stem-cell </span>
   <span class="font11">therapy </span>
   <span class="font11">years </span>
   <span class="font11">Blood </span>
   <span class="font11">days </span>
   <span class="font11">followed </span>
   <span class="font11">regimen </span>
   <span class="font11">.%-.%) </span>
   <span class="font11">Lymphoma </span>
   <span class="font11">Median </span>
   <span class="font11">PCNSL, </span>
   <span class="font11">analysis </span>
   <span class="font11">induction </span>
   <span class="font11">phase </span>
   <span class="font11">radiotherapy </span>
   <span class="font11">relapsed </span>
   <span class="font11">(.%) </span>
   <span class="font11">.-.; </span>
   <span class="font11">NHL </span>
   <span class="font11">Transplant </span>
   <span class="font11">cycles </span>
   <span class="font11">etoposide, </span>
   <span class="font11">included </span>
   <span class="font11">patient </span>
   <span class="font11">patients. </span>
   <span class="font11">results </span>
   <span class="font11">thiotepa </span>
   <span class="font10">%-%) </span>
   <span class="font10">HR, </span>
   <span class="font10">IQR </span>
   <span class="font10">Survival </span>
   <span class="font10">busulfan </span>
   <span class="font10">cyclophosphamide, </span>
   <span class="font10">defined </span>
   <span class="font10">long-term </span>
   <span class="font10">patients; </span>
   <span class="font10">px; </span>
   <span class="font10">received </span>
   <span class="font10">studies </span>
   <span class="font10">trial </span>
   <span class="font10">vincristine, </span>
   <span class="font10">{font-family </span>
   <span class="font10">&amp;gt; </span>
   <span class="font10">CR. </span>
   <span class="font10">HD-MTX </span>
   <span class="font10">However, </span>
   <span class="font10">Illerhaus </span>
   <span class="font10">Karnofsky </span>
   <span class="font10">Marrow </span>
   <span class="font10">benefit </span>
   <span class="font10">compared </span>
   <span class="font10">complete </span>
   <span class="font10">efficacy </span>
   <span class="font10">font-size </span>
   <span class="font10">high </span>
   <span class="font10">lymphoma; </span>
   <span class="font10">neurotoxicity </span>
   <span class="font10">occurred </span>
   <span class="font10">patients) </span>
   <span class="font10">refractory </span>
   <span class="font10">treatment </span>
   <span class="font10">(IQR, </span>
   <span class="font10">.). </span>
   <span class="font10">ASCT, </span>
   <span class="font10">Autologous </span>
   <span class="font10">Data </span>
   <span class="font10">Leuk </span>
   <span class="font10">Relapse </span>
   <span class="font10">Soussain </span>
   <span class="font10">TRM </span>
   <span class="font10">conditioning. </span>
   <span class="font10">cytarabine, </span>
   <span class="font10">diagnosed </span>
   <span class="font10">double; </span>
   <span class="font10">doxorubicin, </span>
   <span class="font10">group </span>
   <span class="font10">intraocular </span>
   <span class="font10">months </span>
   <span class="font10">newly </span>
   <span class="font10">non-Hodgkin </span>
   <span class="font10">number </span>
   <span class="font10">rates </span>
   <span class="font10">toxicity </span>
   <span class="font10">whole-brain </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">(.%). </span>
   <span class="font10">(rituximab, </span>
   <span class="font10">.%-.%), </span>
   <span class="font10">A.J.M. </span>
   <span class="font10">ASCT. </span>
   <span class="font10">Abbreviations: </span>
   <span class="font10">BEAM </span>
   <span class="font10">Elsevier </span>
   <span class="font10">Ferreri </span>
   <span class="font10">Group </span>
   <span class="font10">Haematol </span>
   <span class="font10">Myeloma </span>
   <span class="font10">Value </span>
   <span class="font10">abnormalities </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">carmustine </span>
   <span class="font10">centre </span>
   <span class="font10">consecutive </span>
   <span class="font10">consolidative </span>
   <span class="font10">cytarabine </span>
   <span class="font10">date </span>
   <span class="font10">developed </span>
   <span class="font10">dexamethasone, </span>
   <span class="font10">effects </span>
   <span class="font10">febrile </span>
   <span class="font10">follow-up </span>
   <span class="font10">given </span>
   <span class="font10">infection </span>
   <span class="font10">lymphoma. </span>
   <span class="font10">outcome </span>
   <span class="font10">platelet </span>
   <span class="font10">postremission </span>
   <span class="font10">promising </span>
   <span class="font10">randomized </span>
   <span class="font10">rescue </span>
   <span class="font10">results. </span>
   <span class="font10">score </span>
   <span class="font10">solid; </span>
   <span class="font10">status </span>
   <span class="font10">systemic </span>
   <span class="font10">trials </span>
   <span class="font10">used </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(.%), </span>
   <span class="font10">(.%; </span>
   <span class="font10">(PCNSL) </span>
   <span class="font10">Age </span>
   <span class="font10">Ann </span>
   <span class="font10">CI) </span>
   <span class="font10">COVID- </span>
   <span class="font10">CR, </span>
   <span class="font10">Central </span>
   <span class="font10">Chen </span>
   <span class="font10">Intensive </span>
   <span class="font10">J.L. </span>
   <span class="font10">Kaplan-Meier </span>
   <span class="font10">Kasenda </span>
   <span class="font10">Overall </span>
   <span class="font10">Primary </span>
   <span class="font10">Progression-free </span>
   <span class="font10">Range </span>
   <span class="font10">Toxicity </span>
   <span class="font10">Transplantation </span>
   <span class="font10">Treatment </span>
   <span class="font10">age </span>
   <span class="font10">agents </span>
   <span class="font10">appears </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">brain </span>
   <span class="font10">common </span>
   <span class="font10">compare </span>
   <span class="font10">conditioning, </span>
   <span class="font10">confidence </span>
   <span class="font10">courier; </span>
   <span class="font10">death </span>
   <span class="font10">diagnosis </span>
   <span class="font10">did </span>
   <span class="font10">electrolyte </span>
   <span class="font10">em; </span>
   <span class="font10">encouraging </span>
   <span class="font10">evaluated </span>
   <span class="font10">experience </span>
   <span class="font10">first-line </span>
   <span class="font10">function </span>
   <span class="font10">greater </span>
   <span class="font10">hematopoietic </span>
   <span class="font10">intrathecal </span>
   <span class="font10">large </span>
   <span class="font10">lymphoma, </span>
   <span class="font10">marrow </span>
   <span class="font10">mg/m </span>
   <span class="font10">mucositis, </span>
   <span class="font10">nonmyeloablative </span>
   <span class="font10">noted </span>
   <span class="font10">overall </span>
   <span class="font10">penetration </span>
   <span class="font10">performed </span>
   <span class="font10">poor </span>
   <span class="font10">present </span>
   <span class="font10">progression-free </span>
   <span class="font10">pt;} </span>
   <span class="font10">recovery </span>
   <span class="font10">regimens </span>
   <span class="font10">relapsed/refractory </span>
   <span class="font10">remission </span>
   <span class="font10">remission; </span>
   <span class="font10">resource </span>
   <span class="font10">retrospective </span>
   <span class="font10">rituximab, </span>
   <span class="font10">second </span>
   <span class="font10">shown </span>
   <span class="font10">significant </span>
   <span class="font10">statistically </span>
   <span class="font10">study, </span>
   <span class="font10">transplant </span>
   <span class="font10">treatment-related </span>
   <span class="font10">univariate </span>
   <span class="font10">use </span>
   <span class="font10">vs. </span>
   <span class="font10">years. </span>
  </p>
 </body>
</html>
